Van Lanschot Kempen NV (AMS:VLK)
Netherlands · Delayed Price · Currency is EUR | Market Cap | 2.36B +13.6% |
| Revenue (ttm) | 758.70M +4.5% |
| Net Income | 148.40M +4.7% |
| EPS | n/a |
| Shares Out | 42.37M |
| PE Ratio | 15.87 |
| Forward PE | 14.87 |
| Dividend | 3.80 (6.83%) |
| Ex-Dividend Date | May 25, 2026 |
| Volume | 86,706 |
| Average Volume | 92,227 |
| Open | 55.90 |
| Previous Close | 55.80 |
| Day's Range | 55.00 - 56.50 |
| 52-Week Range | 38.00 - 59.80 |
| Beta | 0.82 |
| RSI | 63.90 |
| Earnings Date | Feb 26, 2026 |
About Van Lanschot Kempen NV
Van Lanschot Kempen NV provides various financial services in the Netherlands, Belgium, and internationally. It operates through four segments: Private Clients Netherlands, Private Clients Belgium, Investment Management Clients, and Investment Banking Clients. The company offers private banking services for entrepreneurs, family businesses, high-net-worth individuals, business professionals and executives, foundations and associations, and affluent individuals; and pension funds. It also provides wealth management services and products, an onli... [Read more]
Financial Performance
In 2025, Van Lanschot Kempen NV's revenue was 758.70 million, an increase of 4.50% compared to the previous year's 726.04 million. Earnings were 148.40 million, an increase of 12.55%.
Financial StatementsNews
Van Lanschot Kempen NV (STU:VA3) Full Year 2025 Earnings Call Highlights: Strong Profit Growth ...
Van Lanschot Kempen NV (STU:VA3) Full Year 2025 Earnings Call Highlights: Strong Profit Growth and Strategic AI Integration
A market correction? We're in stage 3 out of 5, strategist says
Are we on track for a market correction? Joost Van Leenders from Van Lanschot Kempen addresses the latest concerns raised by the IMF and the BOE over high AI-related valuations.
IMF and Bank of England warnings of an AI bubble fits a pattern, strategist says
Joost van Leenders, senior investment strategist at Dutch asset manager Van Lanschot Kempen, discusses the prospect of an artificial intelligence bubble, and the potential ramifications for global sto...
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to add...